EP1691815A4 - SUPEROXIDE DISMUTASE MIMETICS FOR THE TREATMENT OF OPTIC AND RETINA DAMAGE - Google Patents

SUPEROXIDE DISMUTASE MIMETICS FOR THE TREATMENT OF OPTIC AND RETINA DAMAGE

Info

Publication number
EP1691815A4
EP1691815A4 EP04812365A EP04812365A EP1691815A4 EP 1691815 A4 EP1691815 A4 EP 1691815A4 EP 04812365 A EP04812365 A EP 04812365A EP 04812365 A EP04812365 A EP 04812365A EP 1691815 A4 EP1691815 A4 EP 1691815A4
Authority
EP
European Patent Office
Prior art keywords
treatment
superoxide dismutase
optic nerve
retinal damage
dismutase mimics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04812365A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1691815A1 (en
Inventor
Peter G Klimko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of EP1691815A1 publication Critical patent/EP1691815A1/en
Publication of EP1691815A4 publication Critical patent/EP1691815A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
EP04812365A 2003-12-11 2004-11-30 SUPEROXIDE DISMUTASE MIMETICS FOR THE TREATMENT OF OPTIC AND RETINA DAMAGE Withdrawn EP1691815A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52883003P 2003-12-11 2003-12-11
PCT/US2004/039830 WO2005060974A1 (en) 2003-12-11 2004-11-30 Superoxide dismutase mimics for the treatment of optic nerve and retinal damage

Publications (2)

Publication Number Publication Date
EP1691815A1 EP1691815A1 (en) 2006-08-23
EP1691815A4 true EP1691815A4 (en) 2010-03-31

Family

ID=34710102

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04812365A Withdrawn EP1691815A4 (en) 2003-12-11 2004-11-30 SUPEROXIDE DISMUTASE MIMETICS FOR THE TREATMENT OF OPTIC AND RETINA DAMAGE

Country Status (12)

Country Link
US (3) US20070060557A1 (cg-RX-API-DMAC7.html)
EP (1) EP1691815A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007513948A (cg-RX-API-DMAC7.html)
KR (1) KR20060101501A (cg-RX-API-DMAC7.html)
CN (1) CN1889961A (cg-RX-API-DMAC7.html)
AU (1) AU2004305531B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0417549A (cg-RX-API-DMAC7.html)
CA (1) CA2545762A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06006187A (cg-RX-API-DMAC7.html)
RU (1) RU2006124746A (cg-RX-API-DMAC7.html)
WO (1) WO2005060974A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603347B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1889961A (zh) * 2003-12-11 2007-01-03 爱尔康公司 用于治疗视神经和视网膜损伤的超氧化物歧化酶拟似物
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US20190388548A1 (en) * 2018-06-26 2019-12-26 Tzu Chi University Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051458A1 (en) * 2001-12-14 2003-06-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
DE3773926D1 (de) * 1987-07-22 1991-11-21 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung.
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
SE9402816D0 (sv) * 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) * 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
ES2240101T3 (es) 1999-05-27 2005-10-16 Monsanto Company Biomateriales modificados con mimeticos de superoxido dismutasa.
CN1889961A (zh) * 2003-12-11 2007-01-03 爱尔康公司 用于治疗视神经和视网膜损伤的超氧化物歧化酶拟似物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051458A1 (en) * 2001-12-14 2003-06-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991, SZABO M E ET AL: "ISCHEMIA AND REPERFUSION-INDUCED HISTOLOGIC CHANGES IN THERAT RETINA DEMONSTRATION OF A FREE RADICAL-MEDIATED MECHANISM", XP002236627, retrieved from BIOSIS *
SALVEMINI D ET AL: "A NONPEPTIDYL MIMIC OF SUPEROXIDE DISMUTASE WITH THERAPEUTIC ACTIVITY IN RATS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 286, 8 October 1999 (1999-10-08), pages 304 - 306, XP000971099, ISSN: 0036-8075 *
See also references of WO2005060974A1 *
SZABO M E ET AL: "ISCHEMIA AND REPERFUSION-INDUCED SODIUM POTASSIUM CALCIUM AND MAGNESIUM SHIFTS IN RAT RETINA EFFECTS OF TWO FREE RADICAL SCAVENGERS SOD AND EGB 761", EXPERIMENTAL EYE RESEARCH, vol. 55, no. 1, 1992, pages 39 - 45, XP022970052, ISSN: 0014-4835 *

Also Published As

Publication number Publication date
AU2004305531A1 (en) 2005-07-07
WO2005060974A1 (en) 2005-07-07
AU2004305531B2 (en) 2009-11-26
US20070060557A1 (en) 2007-03-15
US20110105453A1 (en) 2011-05-05
US20050130951A1 (en) 2005-06-16
CN1889961A (zh) 2007-01-03
ZA200603347B (en) 2009-02-25
MXPA06006187A (es) 2006-08-25
CA2545762A1 (en) 2005-07-07
EP1691815A1 (en) 2006-08-23
KR20060101501A (ko) 2006-09-25
RU2006124746A (ru) 2008-01-20
JP2007513948A (ja) 2007-05-31
BRPI0417549A (pt) 2007-03-27

Similar Documents

Publication Publication Date Title
EP1581212A4 (en) SUPEROXIDE DISMUTASE IMITATIONS FOR THE TREATMENT OF EYE DISORDERS AND DISEASES
IL291162A (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
TWI369996B (en) Ophthalmic compositions and methods for treating eyes
EP1592435A4 (en) EYE FORMULATION FOR THE PREVENTION AND TREATMENT OF EYE DRESS
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
HUE063927T2 (hu) Szemallergiák kezelésében alkalmazott eljárások és szemészeti eszközök
MX301561B (en) Use of transmission dyes for protecting human skin from browning and ageing
PL1641915T3 (pl) Naprawa i regeneracja tkanek oka z wykorzystaniem komórek otrzymanych poporodowo
FI20010898A0 (fi) Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
EP1708757A4 (en) USE OF PLURIPOTENTIAL CELLS TAKEN FROM HUMAN CORDIAL BLOOD BLOOD FOR THE TREATMENT OF DISEASE
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
EP1812077A4 (en) MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING A FIBROSIS-ASSOCIATED DISEASE
PL1884234T3 (pl) Środek profilaktyczny lub leczniczy w zaburzeniach rogówkowych i spojówkowych
AU2003272204A8 (en) Neuronal and retinal gene expression patterns
IL176227A0 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
ZA200603347B (en) Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
AU2003243405A1 (en) Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
HK1095516A (en) Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
PL1812797T3 (pl) Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom
AU2003250912A8 (en) Agents and methods for diagnosis and therapy of cancer and cancer risk assessment
HK1087612A (en) Superoxide dismutase mimics for the treatment of ocular disorders and diseases
HK1084315A (en) Superoxide dismutase mimics for the treatment of ocular disorders and diseases
GB0523964D0 (en) The treatment of ophthalmic diseases
AU2003240254A1 (en) Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1095516

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20100302

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/555 20060101AFI20050714BHEP

Ipc: A61K 9/20 20060101ALI20100224BHEP

Ipc: A61K 9/00 20060101ALI20100224BHEP

Ipc: A61K 9/08 20060101ALI20100224BHEP

Ipc: A61P 27/00 20060101ALI20100224BHEP

Ipc: A61P 27/02 20060101ALI20100224BHEP

17Q First examination report despatched

Effective date: 20100607

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20110930

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1095516

Country of ref document: HK